India needs innovative strategies to eliminate TB

India Needs Innovative Strategies to Eliminate TB

1. At a Glance

• Tuberculosis (TB) remains the world's deadliest infectious disease — killing more people annually than even COVID-19 at its peak — caused by Mycobacterium tuberculosis [S1, S4].
• India bears the single highest TB burden globally and has set an elimination target of 2025, five years ahead of the UN SDG goal of 2030 [S2].
• The topic sits at the intersection of GS-II (Health Policy) and GS-III (Science & Technology), testing knowledge of India's programmatic response AND the frontier of TB vaccine science.
• A June 2026 article co-authored by former ICMR DG and former WHO Chief Scientist argues that new vaccine trial data and differentiated strategies are essential — signalling policy debates likely to surface in UPSC essays and Mains [S4].

2. Why in the News

• June 6, 2026 — An op-ed in The Hindu by Dr. Balram Bhargava (former Director-General, ICMR) and Dr. Soumya Swaminathan (former Chief Scientist, WHO) highlighted new Indian vaccine trial data showing meaningful protection against extrapulmonary TB (EPTB), calling for targeted vaccination strategies alongside stronger public health measures [S4].
• March 2025 (World TB Day) — PIB released data confirming 21% reduction in TB incidence and 28% reduction in TB deaths in India between 2015–2024 per the WHO Global TB Report 2025 [S1].
• 2025 deadline for India's own elimination target passed without full achievement, renewing debate on innovation gaps [S2].
• India approved a new shorter, more efficacious treatment regimen for drug-resistant TB (DR-TB) — a major policy milestone announced by the Union Health Ministry [S3].

3. Background & Evolution

4. Core Static Facts

Disease Classification: - Pulmonary TB (PTB) — affects lungs; infectious; drives transmission - Extrapulmonary TB (EPTB) — affects organs beyond lungs (lymph nodes, spine, brain, kidneys etc.); harder to diagnose; more debilitating; sometimes fatal [S4] - Subclinical TB — harbouring infection with minimal/no symptoms; a significant reservoir [S4] - Latent TB Infection (LTBI) — asymptomatic; reactivates under immunosuppression

Key Programme Facts: | Parameter | Detail | |-----------|--------| | Nodal Ministry | Ministry of Health & Family Welfare | | Programme | National Tuberculosis Elimination Programme (NTEP) | | Parent Body | Central TB Division (CTD), MoHFW | | Treatment Framework | DOTS (Directly Observed Treatment Short-course) | | Elimination Target | 2025 (India); 2030 (WHO End TB Strategy) | | Diagnostic Network | 9,800+ rapid molecular testing (CBNAAT/TrueNat) facilities — world's largest [S1] | | Lab Network | 107 Culture & Drug Susceptibility Testing (C-DST) labs [S1] | | TB Notification | Mandatory since 2012; all providers must notify | | NSP Pillars | Detect, Treat, Prevent, Build | | Incidence Rate (India, 2023) | ~193 per 1,00,000 (WHO Global TB Report 2023) | | India's share of global burden | ~26–28% of global TB cases |

Key Schemes: - Ni-kshay Poshan Yojana — ₹500/month nutritional support to TB patients - Ni-kshay — IT-based patient tracking system - PMTBMBA — community-driven support; Ni-kshay Mitras (donors/supporters) [S5] - Universal Drug Susceptibility Testing (UDST) — test all patients for drug resistance before treatment

5. Multi-Dimensional Analysis

Economic

• TB kills working-age adults predominantly → loss of productive years; catastrophic health expenditure for poor households.
• Drug-resistant TB treatment is 100x more expensive than drug-sensitive TB; new shorter BPaL regimen (Bedaquiline–Pretomanid–Linezolid) reduces cost and duration [S3].
• WHO estimates TB causes India ~$23 billion in economic losses annually; elimination would unlock demographic dividend potential.

Social

• TB disproportionately affects malnourished populations, urban slum dwellers, migrants, diabetics (co-morbidity), and HIV-positive individuals — all vulnerable groups [S2].
• Stigma remains a major barrier; EPTB affecting bones/lymph nodes is often misdiagnosed for months, worsening outcomes particularly for women and children [S4].
• Ni-kshay Mitras model attempts community-level social support — a novel governance innovation [S5].

Scientific / Technological

• BCG vaccine (1921) protects neonates against severe TB but offers inadequate protection to adolescents and adults — the critical gap [S4].
• M72/AS01E (GSK/Gates Foundation) — completed Phase IIb; showed ~50% efficacy against pulmonary TB; Phase III trials ongoing; new data suggest EPTB protection [S4].
• BCG revaccination — being studied as a booster strategy; modelling suggests could avert ~8.8% of Delhi TB cases 2025–50.
• VPM1002 (a recombinant BCG) — Phase III trial conducted in India (ICMR-led); results awaited.
• New diagnostics: TrueNat (India-developed portable molecular test), CBNAAT, WHO-endorsed AI-based chest X-ray tools [S1].
• Shorter treatment regimens: 6-month BPaL regimen for XDR-TB approved by Health Ministry [S3].

Administrative

• Ni-kshay platform — digital patient management; links lab results, drug supply, and treatment outcomes.
• Private sector accounts for ~50% of TB care-seeking in India; NTEP–Private Sector engagement via cascade of notifications is a persistent bottleneck.
• 100-Day TB Elimination Campaign (2023–24) aimed at intensified case-finding at sub-district level [S6].
• State-level variation: Himachal Pradesh, Kerala performing well; UP, Bihar, MP lag — federal challenge [S2].

Ethical / Governance

• PMTBMBA's Ni-kshay Mitra model raises questions of accountability: private donors adopt TB patients — potential for commodification or stigmatisation [S5].
• Mandatory notification creates a privacy–public health tension for patients.
• Drug supply chain failures (stockouts of second-line drugs) have caused treatment interruptions — an ethical failure of the health system.

Geopolitical / Strategic

• India chairs Stop TB Partnership board periodically; active in shaping WHO End TB targets.
• BRICS TB burden: India, China, and South Africa together account for >40% of global TB — scope for BRICS-level R&D collaboration.
• India–WHO partnership: Soumya Swaminathan (co-author of June 2026 article) symbolises India's scientific leadership in global TB discourse [S4].

6. Recent Developments (Last 12–18 Months)

• March 2025 (World TB Day, March 24) — PIB confirmed 21% decline in TB incidence (2015–2024) and 28% fall in mortality (2015–2024) citing WHO Global TB Report 2025 [S1].
• 2024 — Ministry of Health approved new shorter BPaL/BPaLM regimen for drug-resistant TB, reducing treatment from 18–24 months to ~6 months [S3].
• 2024 — PIB article titled "India Speeding Towards TB Elimination" highlighted NTEP progress including 9,800+ rapid testing facilities and 107 C-DST labs [S1].
• 100-Day TB Elimination Campaign (2023–24) — intensive sub-district case-finding drive [S6].
• June 6, 2026 — Bhargava & Swaminathan op-ed calls for differentiated vaccine strategies targeting EPTB and high-risk sub-populations rather than a "one-shot" universal approach [S4].
• PMTBMBA (launched September 2022) expanded with Ni-kshay Mitras across states, linking benefactors to TB patients for nutritional and social support [S5].

7. Prelims Hooks

1. India's self-set TB elimination target: 2025 (global SDG target: 2030).
2. TB is caused by Mycobacterium tuberculosis; it is an airborne disease.
3. National Tuberculosis Elimination Programme (NTEP) is the renamed form of RNTCP (renamed 2017).
4. Ni-kshay Poshan Yojana provides ₹500/month nutritional support to TB patients — under MoHFW.
5. Pradhan Mantri TB Mukt Bharat Abhiyaan was launched by President Droupadi Murmu in September 2022.
6. India operates the world's largest network of rapid molecular TB testing: 9,800+ facilities [S1].
7. TrueNat — India-developed portable molecular TB diagnostic device (point-of-care); eligible for NTEP procurement.
8. VPM1002 — recombinant BCG-based TB vaccine candidate; Phase III trial conducted by ICMR in India.
9. M72/AS01E — TB vaccine candidate developed by GSK in partnership with the Gates Foundation; showed ~50% efficacy in Phase IIb.
10. BCG (Bacillus Calmette-Guérin) was introduced in 1921 — still the only licensed TB vaccine over 100 years later.
11. Extrapulmonary TB (EPTB) affects organs other than the lungs; it is non-infectious but harder to diagnose than pulmonary TB [S4].
12. Universal Drug Susceptibility Testing (UDST) — NTEP policy mandating all TB patients be tested for drug resistance before treatment initiation.
13. India's TB incidence declined 21% from 2015 to 2024 (WHO Global TB Report 2025) [S1].
14. TB deaths in India declined 28% from 2015 to 2024 [S1].
15. Nodal Ministry for NTEP: Ministry of Health & Family Welfare; implementing body: Central TB Division (CTD).

8. Mains Relevance

GS Paper Mapping:

Plausible Mains Question Stems:

1. "Despite India's ambitious 2025 TB elimination target, the country faces structural barriers that no single technological intervention can overcome. Critically analyse the gaps in India's National Tuberculosis Elimination Programme and suggest a multi-pronged strategy." (GS-II, 15M)

2. "New TB vaccine candidates like M72/AS01E signal a breakthrough but also reveal the limits of a 'one-size-fits-all' vaccine approach. Examine the scientific and public health challenges in developing an effective TB vaccine for adults, with reference to India's burden." (GS-III, 10M)

3. "The Pradhan Mantri TB Mukt Bharat Abhiyaan's Ni-kshay Mitra model blurs the line between state responsibility and philanthropic voluntarism. Evaluate its potential and ethical concerns in the context of universal health coverage." (GS-II/GS-IV, 15M)

9. Related Topics to Study Next

10. Common Errors / Trap Areas

1. Wrong year for NTEP renaming — RNTCP was renamed NTEP in 2017, not 2019 or 2020. Aspirants often confuse this with the NSP 2017–25 launch.
2. Confusion between elimination and eradication — India targets TB elimination (< 1 case per 10 lakh population), not eradication (zero global cases). These are distinct public health thresholds.
3. PMTBMBA launched by PM vs. President — It was launched by President Droupadi Murmu (not PM Modi), at Rudrapur, Uttarakhand, in September 2022 [S5].
4. BCG protects everyone equally — WRONG — BCG offers strong protection to neonates against severe/miliary TB but has variable and limited efficacy in adolescents and adults — a classic trap for science questions [S4].
5. Ni-kshay = Ni-kshay Poshan Yojana — WRONG — Ni-kshay is the IT-based patient tracking portal; Ni-kshay Poshan Yojana is the ₹500/month nutritional support scheme; Ni-kshay Mitra refers to community supporters under PMTBMBA. These are three distinct but related elements.

11. Sources

• [S1] World Tuberculosis (TB) Day – 2025 — PIB Press Release (PRID: 2114549) — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2114549 — (Tier 1)
• [S2] Towards a TB-Free India: Achievements, Challenges and the Way Forward — PIB — https://www.pib.gov.in/PressReleaseIframePage.aspx?PRID=2070942 — (Tier 1)
• [S3] Union Health Ministry approves introduction of new shorter and more efficacious treatment regimen for drug-resistant TB in India — PIB — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2052515 — (Tier 1)
• [S4] India needs innovative strategies to eliminate TB — Balram Bhargava & Soumya Swaminathan, The Hindu, June 6, 2026 — https://www.thehindu.com/todays-paper/2026-06-06/th_international/articleG52G2U9EM-14847457.ece — (Tier 4 / User-supplied primary source)
• [S5] President Droupadi Murmu launches Pradhan Mantri TB Mukt Bharat Abhiyaan — PIB (PRID: 1858006) — https://www.pib.gov.in/PressReleasePage.aspx?PRID=1858006 — (Tier 1)
• [S6] India's 100-Day TB Elimination Campaign — PIB — https://www.pib.gov.in/PressReleaseIframePage.aspx?PRID=2081662 — (Tier 1)